Antithrombotic therapy: triple therapy or triple threat?

Lloyd-Jones, 2004, Lifetime risk for development of atrial fibrillation: The Framingham Heart Study, Circulation, 110, 1042, 10.1161/01.CIR.0000140263.20897.42

Connolly, 2006, Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial, Lancet, 367, 1903, 10.1016/S0140-6736(06)68845-4

Gage, 2001, Validation of clinical classification schemes for predicting stroke: Results from the national registry of atrial fibrillation, JAMA, 285, 2864, 10.1001/jama.285.22.2864

Hart, 2007, Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann Intern Med, 146, 857, 10.7326/0003-4819-146-12-200706190-00007

You, 2012, Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest, 141, e531S, 10.1378/chest.11-2304

Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561

Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638

Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039

1994, Case records of the Massachusetts General Hospital (case 22-1994), N Engl J Med, 330, 1599

Yusuf, 2001, Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N Engl J Med, 345, 494, 10.1056/NEJMoa010746

Leon, 1998, A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators, N Engl J Med, 339, 1665, 10.1056/NEJM199812033392303

Park, 2010, Duration of dual antiplatelet therapy after implantation of drug-eluting stents, N Engl J Med, 362, 1374, 10.1056/NEJMoa1001266

Valgimigli, 2010, Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY), Am Heart J, 160, 804, 10.1016/j.ahj.2010.07.034

Byrne, 2009, Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study, Am Heart J, 157, 620, 10.1016/j.ahj.2008.12.019

Lemesle, 2011, Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: A review of the current guidelines and literature, Hosp Pract (Minneap), 39, 32, 10.3810/hp.2011.10.920

Antman, 1999, Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial, Circulation, 100, 1593, 10.1161/01.CIR.100.15.1593

Oler, 1996, Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis, JAMA, 276, 811, 10.1001/jama.1996.03540100055028

Rothberg, 2005, Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: Meta-analysis with estimates of risk and benefit, Ann Intern Med, 143, 241, 10.7326/0003-4819-143-4-200508160-00005

Andreotti, 2006, Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: An updated and comprehensive meta-analysis of 25,307 patients, Eur Heart J, 27, 519, 10.1093/eurheartj/ehi485

Holmes, 2009, Combining antiplatelet and anticoagulant therapies, J Am Coll Cardiol, 54, 95, 10.1016/j.jacc.2009.03.044

Ruiz-Nodar, 2008, Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis, J Am Coll Cardiol, 51, 818, 10.1016/j.jacc.2007.11.035

Khurram, 2006, Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding, J Invasive Cardiol, 18, 162

DeEugenio, 2007, Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy, Pharmacotherapy, 27, 691, 10.1592/phco.27.5.691

Karjalainen, 2007, Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting, Eur Heart J, 28, 726, 10.1093/eurheartj/ehl488

Sarafoff, 2008, Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation, J Intern Med, 264, 472, 10.1111/j.1365-2796.2008.01989.x

Rossini, 2008, Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy, Am J Cardiol, 102, 1618, 10.1016/j.amjcard.2008.08.021

Alexander, 2009, Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial, Circulation, 119, 2877, 10.1161/CIRCULATIONAHA.108.832139

Alexander, 2011, Apixaban with antiplatelet therapy after acute coronary syndrome, N Engl J Med, 365, 699, 10.1056/NEJMoa1105819

Mega, 2009, Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial, Lancet, 374, 29, 10.1016/S0140-6736(09)60738-8

Mega, 2012, Rivaroxaban in patients with a recent acute coronary syndrome, N Engl J Med, 366, 9, 10.1056/NEJMoa1112277

Lip, 2010, Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary–a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), Eur Heart J, 31, 1311, 10.1093/eurheartj/ehq117

Dewilde, 2009, Design and rationale of the WOEST trial: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST), Am Heart J, 158, 713, 10.1016/j.ahj.2009.09.001